Sort
10,766 grants matching “checkpoint inhibitor”
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
$623,817Meenakshi G Hegde · Baylor College Of Medicine · R01 · FY2024 · CA
Adoptive T Cell Therapy for Pancreatic Cancer
$623,803Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Adoptive T Cell Therapy for Pancreatic Cancer
$623,803Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Adoptive T Cell Therapy for Pancreatic Cancer
$623,803Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
$623,787Paul E Kinahan · University Of Washington · U24 · FY2022 · CA
Innate NLRC4 signaling controls adaptive immune responses
$623,783Fayyaz S. Sutterwala · Cedars-Sinai Medical Center · R01 · FY2024 · AI
Preclinical and Clinical Models of Drug Induced Kidney Injury
$623,715Melanie S Joy · University Of Colorado Denver · R01 · FY2025 · CA
Radiogenomic Credentialing of Head and Neck Cancer Models
$623,637Mukund Seshadri · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
IDENTIFYING BIOMARKERS AND DISSECTING COMBINATORIAL SYNERGIES TO IMPROVE IMMUNE CHECKPOINT INHIBITOR RESPONSE IN BLADDER CANCER
$623,580The Cleveland Clinic Foundation · · FY2020 · Defense Health Agency
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$623,527Edward B Garon · University Of California Los Angeles · R01 · FY2025 · CA
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
$623,480Calvin J Kuo · Stanford University · R01 · FY2024 · CA
Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling
$623,452Jae-Il Park · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Metallo-fluorocarbon nanoemulsion for PET detection of cancer inflammation
$622,917Eric T Ahrens · University Of California, San Diego · R01 · FY2024 · CA
Targeting Non Viral Markers of HIV Persistence
$622,821Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2022 · AI
UBR5's mechanisms of action in tumorigenesis and immunoregulation
$622,468Xiaojing Ma · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
$622,286Stephen R. Bowen · University Of Washington · R01 · FY2022 · CA
Interrogating the role of arachidonic acid metabolism in modulating the tumor immune microenvironment as a novel path to therapeutic intervention
$622,227Timothy J Yeatman · University Of South Florida · U01 · FY2025 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$622,068Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2022 · CA
A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment
$622,059Richard T Lee · Beckman Research Institute/City Of Hope · U01 · FY2023 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma
$622,000Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2025 · CA
Glycosylation and Immune Evasion in Urologic Tumors
$621,878Sharon Pitteri · Stanford University · U01 · FY2019 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2023 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$621,867Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2024 · CA
Resistance mechanisms to autophagy-modulating therapies
$621,660Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2024 · CA